aspirina

Highlights TCT 2019

TCT 2019 | TWILIGHT: Minimal DAPT in High Bleeding Risk Patients

Courtesy of the SBHCI. Monotherapy with a P2Y12 inhibitor after a minimum period (3 months) of dual antiplatelet antiaggregation (DAPT) is a valid treatment option to reduce bleeding in patients at high risk of bleeding complications.&nbsp; The present double-blind study presented at TCT 2019 simultaneously published in NEJM analyzed ticagrelor monotherapy (prior 3 months DAPT)<a href="https://solaci.org/en/2019/09/30/tct-2019-twilight-minimal-dapt-in-high-bleeding-risk-patients/" title="Read more" >...</a>

ticagrelor vs. aspirina

Aspirin in Primary Prevention: Another “Trendy” Topic in Publications

Aspirin is the standard treatment when it comes to optimal medical treatment in the context of secondary prevention of coronary artery disease, in patients with diagnosed, established atherosclerosis. Even though bleeding risk is rather small in the short period an acute event takes place, it increases substantially over time. However, the evidence clearly supports the<a href="https://solaci.org/en/2019/06/14/aspirin-in-primary-prevention-another-trendy-topic-in-publications/" title="Read more" >...</a>

ACC 2019 | SMART-CHOICE: la aspirina cada vez más “contra las cuerdas”

ACC 2019 | SMART-CHOICE: Aspirin Increasingly “Against the Ropes”

This work (presented during the same American College of Cardiology [ACC] 2019 Scientific Session as the STOPDAPT-2 trial) enrolled 2993 patients who underwent angioplasty with current-generation stents Xience, Promus, Synergy, or Orsiro at 33 Korean sites. Patients were randomized to 12 months of dual antiplatelet therapy or dropping aspirin at 3 months. There was no difference between the short-<a href="https://solaci.org/en/2019/03/25/acc-2019-smart-choice-aspirin-increasingly-against-the-ropes/" title="Read more" >...</a>

ACC 2019 | POET: los antibióticos vía oral con buenos resultados a largo plazo en endocarditis

ACC 2019 | AUGUSTUS: Apixaban Plus P2Y12 Inhibitor Is the Best Combination in Atrial Fibrillation and Angioplasty

Aspirin increases bleeding with no ischemic benefit, but a trend toward more stent thrombosis with placebo warrants further studies. Patients with atrial fibrillation who receive an anticoagulant agent and coronary angioplasty with a stent, and then continue with aspirin, experience an increased risk of bleeding without any ischemic benefit whatsoever. &nbsp; The use of a<a href="https://solaci.org/en/2019/03/25/acc-2019-augustus-apixaban-plus-p2y12-inhibitor-is-the-best-combination-in-atrial-fibrillation-and-angioplasty/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

Aspirin, Bleeding and Cardiovascular Events in Healthy Elderly

The ASCEND and ARRIVE trials -presented at the European Cardiology Congress and published in The New England Journal of Medicine (NEJM) and The Lancet respectively- have put against the ropes the indication of aspirin in the context of primary prevention. The ASPREE trial, recently published in the NEJM, appears to have definitely overthrown aspirin, since<a href="https://solaci.org/en/2018/12/04/aspirin-bleeding-and-cardiovascular-events-in-healthy-elderly/" title="Read more" >...</a>

ARRIVE: la aspirina en el ojo de la tormenta de la prevención primaria

ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention

Aspirin failed to reach the primary endpoint in a population that was at risk of experiencing cardiovascular disease. However, something that a short time ago seemed obvious could not be proved by randomizing 12,000 patients. The ARRIVE trial, presented at the European Society of Cardiology (ESC) Congress 2018 and simultaneously published in The Lancet, joins the<a href="https://solaci.org/en/2018/08/29/esc-2018-arrive-aspirin-in-the-eye-of-the-storm-of-primary-prevention/" title="Read more" >...</a>

ASCEND: Aspirina para prevención primaria en diabéticos no pasa el costo/beneficio

ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis

The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow of doubt over the indication of aspirin for primary prevention in diabetic patients. According to the ASCEND trial, presented at the European Society of Cardiology (ESC) 2018 Congress and simultaneously published in NEJM, aspirin reduces cardiovascular events as<a href="https://solaci.org/en/2018/08/28/esc-2018-ascend-aspirin-for-primary-prevention-in-diabetic-patients-fails-the-cost-benefit-analysis/" title="Read more" >...</a>

ticagrelor vs. aspirina

Can We Prevent Cardiovascular Events without Aspirin?

As regards the use of antithrombotic agents, the risk of bleeding will always be an issue, and in the case of aspirin this risk is twice as big: it does have the desired antiaggregation effect, but on top of the increased bleeding risk, it has a damaging effect on stomach lining that increases the risk<a href="https://solaci.org/en/2018/07/25/can-we-prevent-cardiovascular-events-without-aspirin/" title="Read more" >...</a>

¿Cómo debemos antiagregar a los pacientes con ACV-AIT? - Interesantes resultados del estudio POINT

What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial

Courtesy of Dr. Alejandro Lakowsky, MTSAC (Full Member of the Argentine Society of Cardiology) The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy (DAPT) with aspirin<a href="https://solaci.org/en/2018/06/06/what-antiplatelet-therapy-should-we-use-in-patients-with-stroke-tia-interesting-results-for-the-point-trial/" title="Read more" >...</a>

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

New Study Shows Ticagrelor + Aspirin Reduce Events Rate

Just when we were starting to understand how long dual antiplatelet therapy should be for our patients,&nbsp;JACC&nbsp;publishes this study where ticagrelor&nbsp;combined with aspirin significantly reduces relative and absolute events rate at long term, especially in patients with multivessel disease. The PEGASUS-TIMI 54 assessed the long-term benefits of two different doses of ticagrelor (60 mg or<a href="https://solaci.org/en/2018/03/21/new-study-shows-ticagrelor-aspirin-reduce-events-rate/" title="Read more" >...</a>

Top